Individual differences in brain dynamics across a social cognition network induced by cortico-cerebellar tDCS in adults with autism spectrum disorder (ASD).

NeuroimageSep 1, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Claudia D Tesche, Joan Esse Wilson

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of cortico-cerebellar transcranial direct current stimulation (tDCS) on brain dynamics in 24 young adults with autism spectrum disorder (ASD). The study found idiosyncratic changes in theta- and alpha-band activity across a social cognition network, with significant correlation between right Crus I/II activity and overall theta-band changes, suggesting potential therapeutic implications for ASD.

Key findings

  • Idiosyncratic up- and down-regulation of theta- and alpha-band activity was observed across the social cognition network.
  • Activity in right Crus I/II correlated strongly with changes in theta-band activity across all cortical nodes.
  • Theta-band stimulation may drive synaptic plasticity in the cerebellar cortex.

Why it matters

Understanding individual differences in brain dynamics can enhance therapeutic approaches for ASD. Targeting specific brain regions with tDCS may improve social cognition and overall functioning in affected individuals.

Source

PubMed · PMID 42680022

Published in Neuroimage. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.